OOIR: Observatory of International Research

Papers

(The H4-Index of JACC: Cardiooncology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Addressing the Overlooked	124
The Pursuit of “Best” Anticoagulant for Cancer-Associated Thrombosis	117
Driven by Impact, Not Impact Factor	107
Full Issue PDF	104
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	99
Preventing Cancer Therapy–Related Cardiotoxicity	88
Atrial Fibrillation in Patients With Cancer	85
LAAO in Cardio-Oncology	81
Full Issue PDF	80
Editorial Board	78
Determining Cause-Specific Mortality in Cancer Survivors	60
Editorial Board	60
JACC: CardioOncology	53
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms	50
Editorial Board	50
Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma	45
Clinical Practice Guidelines in Cardio-Oncology	45
Editorial Board	45
How to Treat Breast Cancer After Childhood Cancer	44
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	43
Embracing the Power of the Polysocial Risk Score	43
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism	42
Understanding and Reducing the Social and Environmental Determinants of Health Disparities in Cardio-Oncology	42
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	41
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support	40

PALLIATIVE RESECTION OF A CARDIAC SARCOMA	40
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	40
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	40
Outcomes of Surgery in Cardiac Angiosarcoma	38
Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy	38
Reply	33
Cardio-Oncology and Health Equity	32
Editorial Board/Officers Page	32